Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)
Completed
- Conditions
- Cardiovascular EventCoronary Artery Bypass GraftDiabetes Mellitus
- Registration Number
- NCT03590223
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 589
Inclusion Criteria
- patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012
Exclusion Criteria
- disapproval of use of data for research purposes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method occurence of Major adverse cardiac events perioperative = in hospital myocardial infarction, cardiac related death, stroke
- Secondary Outcome Measures
Name Time Method occurence of severe renal insufficiency perioperative = in hospital application of renal replacement therapy (renal dialysis)
occurence of sternal wound infection perioperative = in hospital sternal wound infection
mortality perioperative = in hospital death rate perioperative
Trial Locations
- Locations (1)
Herzchirurgie University Hospital Basel
🇨ðŸ‡Basel, Switzerland